Open AccessPhase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas
Author(s) -
Geraldine O’Sullivan Coyne,
Shivaani Kummar,
Robert Meehan,
Khanh Do,
Jerry M. Collins,
Larry D. Anderson,
Kazusa Ishii,
Naoko Takebe,
Jennifer Zlott,
Lamin Juwara,
Richard Piekarz,
Howard Streicher,
Elad Sharon,
Larry Rubinstein,
Andrea Regier Voth,
Jay N. Lozier,
Angie B. Dull,
Deborah Wilsker,
Toshinori Hinoue,
Peter W. Laird,
Katherine V. Ferry-Galow,
Robert J. Kinders,
Ralph E. Parchment,
James H. Doroshow,
Alice Chen
Publication year - 2020
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.27784
Subject(s) - temozolomide , medicine , oncology , cancer research , maximum tolerated dose , clinical trial , glioblastoma
TRC102 inhibits base excision repair by binding abasic sites and preventing AP endonuclease processing; it potentiates the activity of alkylating agents, including temozolomide, in murine models. In published xenograft studies, TRC102 enhanced the antitumor effect of temozolomide regardless of cell line genetic characteristics, e.g., O6-methylguanine DNA methyltransferase (MGMT), mismatch repair (MMR), or p53 status.